ERBB2 and breast cancer: The advent of HER2-targeted agents, particularly trastuzumab, a recombinant humanized monoclonal antibody that is directed towards HER2, has revolutionized the treatment of this aggressive BC subtype, significantly improving overall survival in advanced and primary BC patients.